drugset / Trial / NCT02068053

Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020

NCT02068053

Phase 1 Completed 6 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-label

Summary

The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, as well as safety and tolerability of a single oral solution dose of \[14C\] Bristol-Myers Squibb (BMS)-986020 in healthy male subjects.

Timeline

Start
2014-03
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986020 Small molecule 600 mg Oral